This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BHC Q3 Earnings Preview: Here's What You Should Know
by Zacks Equity Research
Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
BHCPositive Net Change GILDPositive Net Change VRTXPositive Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
by Zacks Equity Research
Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
TNGXNegative Net Change HALOPositive Net Change TGTXPositive Net Change HRMYPositive Net Change
biotechnology biotechs medical pharmaceuticals
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall
by Zacks Equity Research
Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
RDYPositive Net Change HALOPositive Net Change TGTXPositive Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results?
by Sundeep Ganoria
VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts.
VKTXPositive Net Change NVONegative Net Change LLYPositive Net Change
biotechs earnings-preview medical pharmaceuticals
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
by Zacks Equity Research
Moderna falls despite positive phase III cancer therapy data showing reduced melanoma recurrence and metastasis risks, as investors weigh elevated expectations.
MRKNegative Net Change MRNAPositive Net Change HALOPositive Net Change TGTXPositive Net Change
biotechs
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential?
by Ekta Bagri
Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and debt remain key risks.
BMYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains?
by Sundeep Ganoria
Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks.
NVONegative Net Change VKTXPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy
by Zacks Equity Research
AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.
AZNNegative Net Change NVSNegative Net Change TVTXNegative Net Change
biotechs
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?
by Kanishka Das
AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
AXSMPositive Net Change JAZZNegative Net Change ACADPositive Net Change
biotechs
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
by Ahan Chakraborty
NVO's Ozempic and Wegovy sales will be in focus for Q3 results as oral GLP-1 launches expand, while pricing pressure and competition challenge growth.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals